# A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

> **NCT06362044** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 89 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06362044
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362044, "A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06362044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*